About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences is a clinical-stage biotech developing cancer immunotherapies. High beta, no dividend, binary Phase 3 trial catalyst risk. CSP premiums appear rich but extreme event risk from trial readouts makes selling very dangerous. Micro-cap with thin liquidity.
Biotechnology